Management Committee

Our Management Committee includes senior officials from BRANY’s owner institutions. These include NYU Grossman School of Medicine, Montefiore Medical Center, Icahn School of Medicine at Mount Sinai, and  Northwell Health.


Brian P. Currie, M.D., MPH
Brian P. Currie, M.D., MPH previously held the position of  Vice President and Medical Director for Research at Montefiore Medical Center and Assistant Dean for Clinical Research at the Albert Einstein College of Medicine.

Dr. Currie has served in a senior administrative capacity at Montefiore Medical Center, the University Hospital, and Academic Medical Center for the Albert Einstein College of Medicine, for over fifteen years. A regional integrated delivery system, Montefiore operates four hospital divisions with 1500 beds, ambulatory care centers at forty locations, a rehabilitation facility, and a home care program. With 16,000 employees, 100,000 inpatient discharges, 2 million outpatient visits, and an annual operating budget of 2.0 billion, Montefiore ranks among the largest academic medical centers in the country.

Dr. Currie  is a graduate of the Albert Einstein College of Medicine and completed residency training in Internal Medicine at Bellevue Hospital / NYU and an Infectious Diseases Fellowship at AECOM/Montefiore Medical Center. Dr. Currie also received an MPH degree in Epidemiology from the Columbia University School of Public Health. He is board certified in Internal Medicine and Infectious Diseases. He has been on the faculty of the Albert Einstein College of Medicine for the past 20 years and has a joint appointment as Professor of Medicine and Professor of Epidemiology and Population Health.

In addition to his administrative and faculty responsibilities, Dr. Currie practiced medicine in the Division of Infectious Diseases at Montefiore Medical Center and had been actively involved as a principal investigator in grant funded clinical and translational research activities. He is a Fellow of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America and the New York Academy of Medicine.

Dr. Currie also serves as member of the External Advisory Board for the CITI Program, a division of BRANY.

Imad Alsayed, MD, MS
Vice Chairman 
Dr. Alsayed, research associate professor, is Senior Vice President Clinical Research Operations & Regulatory Affairs and Institutional Official at NYU Langone Health. Through the management of the Clinical Research Support Unit and Human Research Regulatory Affairs, which encompasses Human Research Regulatory Services and IRB operations, he oversees the processes and systems that ensure responsible conduct of human subjects research. Additionally, Dr. Alsayed leads strategic relationships with affiliates and other external clinical research partners to develop innovative approaches to clinical trial execution, subject recruitment, trial monitoring, and data analysis.

Prior to joining NYU Langone, Dr. Alsayed gained extensive experience in clinical research through leadership appointments at GlaxoSmithKline, Abbott, Bayer, Covance, and Parexel International. He ran large global and multifunctional clinical development organizations, tasked with conducting phase I through IV clinical trials. He was instrumental in steering strategic transformation initiatives focused on eClinical technology and organizational/process reengineering to improve compliance, quality, and efficiency of human clinical research. In addition, he led new product introduction and real-world evidence generation for several new HIV, cardiovascular, and oncology drugs.

David N. Deutsch
Mr. Deutsch is the Founder and President of David N. Deutsch & Company LLC. Prior to establishing the firm, Mr. Deutsch was Managing Director, Investment Banking at Congress Financial Corporation, a leading lender specializing in the structuring, financing and refinancing of middle-market leveraged acquisitions and troubled companies. Before joining Congress, he was Vice President of Bear, Stearns & Co. Inc., where he directed a wide variety of corporate finance and merger & acquisition transactions for leading middle-market companies. Mr. Deutsch was previously a member of the corporate finance and high-yield and convertible bond departments of Drexel Burnham Lambert Incorporated. He began his career, prior to graduate school, at Lehman Brothers Kuhn Loeb Incorporated. Mr. Deutsch is the author of numerous articles related to, and a frequent speaker on, the subject of mergers, acquisitions and corporate finance. He is a contributing author of The Mergers & Acquisitions Handbook (McGraw-Hill) and has been described as one of the “leading buyout professionals” by Securities Data Publishing. He has been profiled in The Deal, Crain’s New York Business, Corporate Financing Week, Mergers and Corporate Policy and Buyouts, and his comments have appeared in numerous national business publications and news services including The Wall Street Journal, BusinessWeek, Investor’s Business Daily, Corporate Finance, The Secured Lender, The Associated Press and on the Discovery Channel. For six consecutive years, Mr. Deutsch was invited to participate in Mergers & Acquisitions Journal’s prestigious middle-market roundtable.

Mr. Deutsch holds a Bachelor of Arts from Middlebury College and a Master of Business Administration from Columbia University Graduate School of Business, where he delivered the valedictory address on behalf of his class.

He is a member of the Executive Advisory Board of Columbia University Graduate School of Business’ Heilbrunn Center for Graham & Dodd Investing and serves as a Columbia Business School Admissions Ambassador. He is a member of the Family Firm Institute, the Bond Club of New York (one of the oldest and most august associations of Wall Street professionals), and the New York City Investment Fund (organized by Mr. Henry Kravis). Mr. Deutsch is a member of the Board of BRANY (the Biomedical Research Alliance of New York), the New York Chapter of the Association for Corporate Growth and former member of the Advisory Board of the New York Capital Roundtable. He is Trustee and Chairman of the Nominating Committee of the Museum of American Finance in association with the Smithsonian Institution, Founder of the Wall Street Council of the Consolidated Corporate Fund of Lincoln Center for the Performing Arts, member of the Financial Leadership Forum of the Science, Industry and Business Library (New York Public Library), and a former member of the Executive Committee of the Wall Street Division of UJA-Federation.

Donna Drummond
Donna Drummond is Senior Vice President, Chief Expense Officer and Chief Sustainability Officer at Northwell Health. Ms. Drummond is one of the leaders of Northwell Ventures, established to generate and manage partnerships and investments, develop strategies for new business entities and identify novel nonclinical revenue streams for the health system. Previously, she served as the health system’s chief administrative officer and chief procurement officer.

A certified public accountant, Ms. Drummond joined Northwell Health in 2002 as vice president, material support services. In that role, she established a financial reporting and analysis team to execute a proactive procurement strategy of continuous improvement and increased support. In addition, in managing accounts payable, she implemented processes to enhance the monitoring and reduction of expenses.

Ms. Drummond was associate executive director of non-clinical services at Northwell’s tertiary campuses. She then served as the health system’s vice president of value analysis during which time she led a supply expense management project which saved the health system over $100 million in supply-related expenses.

Before coming to Northwell, Ms. Drummond held a number of positions with J.P. Morgan & Co., Inc. where she worked for 15 years. Prior to that, she was employed by Deloitte, Haskins & Sells.

Ms. Drummond holds a Bachelor of Science degree in accounting from Saint John’s University, Queens, NY.

Matt Rosamond
Matt Rosamond, MBA, is Chief Financial Officer for the Icahn School of Medicine at Mount Sinai. A results-oriented operational and financial leader, Mr. Rosamond has 20 years of experience in health care, biotechnology, and genomics. In this role Mr. Rosamond is responsible for leading all financial initiatives across the clinical, research and education missions of the School of Medicine

Mr. Rosamond has held a number of previous roles within the Mount Sinai Health System. From 2019 to 2021 Mr. Rosamond served as the Senior Vice President and Chief Operating Officer of the Mount Sinai Doctors Faculty Practice. In 2017, Mr. Rosamond became co-founder and Chief Financial Officer of Sema4, a Mount Sinai spin-out health intelligence company dedicated to advancing the diagnosis, treatment, and prevention of disease with a focus on genomic testing. Prior to Sema4, Mr. Rosamond worked as the Director of Finance and Business Development for the Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology. Mr. Rosamond began his career at PwC, spending a decade with the firm in their Strategic Advisory and Transaction Services departments.

Mr. Rosamond graduated from New York University’s Stern School of Business with an MBA. He was awarded his CFA Charter by the Chartered Financial Analyst Institute.

Robert L. Van Nostrand
Robert L. Van Nostrand has served on the Biomedical Research Alliance of New York (BRANY) board of directors since 2011.

Mr. Van Nostrand is a consultant who has served as director and chairman for Metabolix, Inc, a Bio-Industrial company since October 2006.  From January 2010 to July 2010, he was executive vice president and chief financial officer of Aureon Laboratories Inc.  From July 2007 until September 2008, Mr. Van Nostrand served as executive vice president and chief financial officer of AGI Dermatics, Inc. Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. from 1986 to 2007, serving as senior vice president and Chief Compliance Officer from May 2005 until July 2007, and as the Vice President and Chief Financial Officer from 1996 through 2005.  Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. (currently Deloitte and Touche).  Mr. Van Nostrand serves on the board of directors and as chairman of the audit committee of Achillion Pharmaceuticals, Inc., serves on the board of directors, is lead outside director, and is chairman of the audit committee of Intra-Cellular Therapies, Inc., and serves on the board, is chairman, as well as chair of the audit committee of Yield 10 Bioscience, and serves on the board and is chair of the compensation committee of Sellas Lifesciences.

Mr. Van Nostrand received a BS in Accounting from Long Island University, New York, completed advanced management studies at the Wharton School, and he is a Certified Public Accountant.